RT Journal Article
SR Electronic
T1 A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4667
VO 44
IS Suppl 58
A1 Gregorino Paone
A1 Luigi Lanata
A1 Patrizio Palermo
A1 Michela Bagnasco
A1 Simona Toti
A1 Federico Saibene
A1 Barbara Moscatelli
A1 Alessandra Monguzzi
A1 Giovanni Puglisi
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/4667.abstract
AB Chronic obstructive pulmonary disease (COPD) is characterised by airway inflammation and oxidative stress contributing to corticosteroid resistance. Carbocysteine lysine salt (CLS) is a mucoactive drug with antinflammatory and antioxidant activities. The PEACE studyshowed a 25%reduction of COPD exacerbations for carbocysteine, with significant benefit in patients with >1 exacerbation, but only 17% of patients received inhaled steroids (IS).This is a prospective real life clinical trial evaluating the effect of CLS on COPD exacerbations in addition to background therapy with or without IS in GOLD stage II-IV patients.As of 31-Jan-2014, 202 patients were included in the study with a minimum 3-month follow-up. Mean age was 69.3 yrs and M/F was 100/102. Of these, 42 patients with >2 exacerbations at baseline (in the previous year) completed the 1-year study period: CLS was added to background therapy including IS in 40.5% and without IS in 59.5%. At 1 year of CLS treatment, only 59.5% of these 42 patients experienced >2 exacerbations,respectively 64.7% and 56% in the group receiving vs. non receiving IS (NS). Also the mean number of exacerbations declined significantly, overall from 2.74 to 1.67 (Δ=-39.1%, p<0.0001): significant improvement was seen both in IS (from 2.94 to 2, Δ=-32%, p=0.0038) and non-IS patients (from 2.6 to 1.44, Δ=-44.6%, p=0.0008), with no significant difference between the 2 groups (p=0.6001).These preliminary results show that addition of CLS allows significant reduction of COPD exacerbations in patients with >2 exacerbations at baseline. At 12 months, the effect of CLS on exacerbations is similar for background therapy with or without IS.